A 23-year-old Caucasian woman developed simultaneous onset longitudinally extensive transverse myelitis (LETM; figure, A.a) and left optic neuritis. She had no significant neurologic history, but her brother had MS. At nadir, she had Medical Research Council grade 2/5 power in the lower limbs and a sensory level at T4. MRI of the brain identified lesions within the right middle cerebellar peduncle (figure, A.b) and adjacent to the posterior horn of the left lateral ventricle (figure, A.c). Oligoclonal bands were present in the CSF, and serum autoantibodies to aquaporin-4 and myelin oligodendrocyte glycoprotein were absent on repeated testing 2 months apart. Visual evoked potentials were abnormal only on the left. Seronegative neuromyelitis optica spectrum disorder (NMOSD) was diagnosed1 and treated with corticosteroids, but she relapsed 2 months later. Azathioprine was added to steroids but she relapsed again 4 months later. Repeat MRI showed fragmentation of the LETM into multiple short cord lesions (figure, B.a) and 2 new juxtaventricular lesions in the brain (figure, B.b and c), more in keeping with MS than NMOSD. She was initiated on natalizumab and has remained without new clinical events for the last 12 months. MRI was repeated 8 months into treatment with natalizumab and confirmed that there were no new lesions.
(A.a) Longitudinally extensive T2-hyperintensity within the spinal cord from C1 to the lower border of C5. (A.b) Lesion within the right middle cerebellar peduncle. (A.c) Lesion adjacent to the posterior horn of the left lateral ventricle. (B.a) Longitudinally extensive transverse myelitis has fragmented into multiple discrete short lesions within the cervical cord. (B.b) New lesion adjacent to the body of the right lateral ventricle. (B.c) New lesion adjacent to the body of the left lateral ventricle.
Discussion.
LETM (myelitis extending over 3 or more vertebral segments) with optic neuritis is considered the sine qua non of NMOSD. By contrast, spinal cord lesions in MS are usually less than 1 vertebral segment in length. However, long myelitis can occur in MS too. It was present in approximately 3% of patients in 2 large case series2,3 and was the presenting demyelinating episode in only 0.7% of cases.3 Contiguous multiple short lesions with edema can also give the appearance of LETM.
In this case, the presentation of optic neuritis and long myelitis led to the diagnosis of NMOSD, but in hindsight, there were several features that could support the diagnosis of MS had it not been for the LETM: Caucasian ethnicity, family history of MS, CSF oligoclonal bands, MS-typical brain lesions, and poor response to azathioprine combined with high-dose corticosteroids. Lesions adjacent to the body of the lateral ventricles (as in the figure, panels B.b and c) are highly sensitive and specific for MS over NMOSD.4 The prompt remission on natalizumab, a drug that is known to be associated with worsening of NMOSD,5 is also supportive of the diagnosis of relapsing-remitting MS.
This case demonstrates a rare radiologic manifestation of MS mimicking a classical presentation of the much rarer NMOSD. The correct diagnosis became clear with time and sequential imaging. In the absence of aquaporin-4 autoantibodies, accurate differentiation between these 2 disorders is not always straightforward, and given that many disease-modifying treatments for MS can exacerbate NMOSD, it is sometimes reasonable to treat with conventional immunosuppressant medications until more certain of the diagnosis.6 While neurologists have become sensitive about the possibility of NMO mimicking MS over the last decade, the possibility of MS masquerading as NMO needs to be periodically considered in all cases of seronegative NMOSD, particularly those remaining unresponsive to treatments.
Acknowledgments
Acknowledgment: The UK NMO Service is funded by the highly specialized commissioning group of NHS England.
Footnotes
Author contributions: Daniel Whittam, Maneesh Bhojak, and Kumar Das: drafting and revising the manuscript. Anu Jacob: study concept and drafting and revising the manuscript.
Study funding: No targeted funding.
Disclosure: D. Whittam, M. Bhojak, and K. Das report no disclosures. A. Jacobs served on the scientific advisory board for Shire Pharmaceuticals; received travel funding and/or speaker honoraria from Biogen Idec, Shire, and Terumo BCT; consulted for Shire Pharmaceuticals; and received research support from Biogen, Alexion Pharmaceuticals, NHS, and University of Liverpool. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.
- Received October 30, 2016.
- Accepted in final form January 4, 2017.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Neuromyelitis optica spectrum disorders in children and adolescents
Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis